skip to Main Content

B-cells are an essential arm of adaptive immunity-in-balance, as their differentiation in response to foreign antigen generates protective immunological memory and antibodies.

Next symposium 11th and 12th of May 2021

Introduction to T2B

B-cells are an essential arm of adaptive immunity-in-balance, as their differentiation in response to foreign antigen generates protective immunological memory and antibodies. When out of balance, aberrant B-cell differentiation and escape from immunological checkpoints governing tolerance and B-cell-selection/activation may lead to pathological, autoreactive, immunological memory and (auto)antibodies. As a result a wide array of immune-mediated diseases (B-IMDs) or malignant transformation of B-cells may follow. Ample evidence indicates successful therapeutic targeting of the B-cell→plasmacell→antibody axis in autoimmune diseases and hematological malignancies. Since almost 10% of the population suffers from either IMDs or lymphoma/leukemia in the Netherlands, there is urgent need for combining B-cell biology expertises across disease fields to optimize therapy efficacy within the fields of B-IMDs and B-cell/plasmacell malignancies. Oncological experience will cross-fertilize and improve IMD treatment approaches possibly leading to cure. IMD-derived B-cell knowledge will fuel development of new treatment strategies in oncology.

Ons afweersysteem

This project has received funding from the PPP allowance (Health Holland), the Association of Dutch Health Foundations (SGF) and our private partners Pfizer B.V., Janssen Vaccines & Prevention B.V., Acerta Pharma B.V., Fresenius and Fluidigm

Partners

Workpackages

WP1

In the Netherlands a range of scientists and clinicians are actively involved in B cell-related research...
Read more

WP2 and WP5

WP2 is dedicated to set-up specialized cellular assays to study the dynamics, diversity and function of B-lymphocyte differentiation in health...
Read more

WP3 and WP6

In workpackage 3 we try to understand the impact of B cell targeted therapy on the repertoire of autoantibodies with respect to...
Read more

WP4

Next to its scientific and clinical ambition, the consortium also aims to develop an outreach program for multiple stakeholders...
Read more

WP7 and WP8

Work package 7 is all about B cell-targeting therapies in B cell-mediated autoimmune diseases and malignancies...
Read more
Back To Top